- Home
- VWAV vs IPHA Comparison
VWAV vs IPHA Comparison
Compare VWAV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VWAV
- IPHA
- Stock Information
- Founded
- VWAV 2024
- IPHA 1999
- Country
- VWAV United States
- IPHA France
- Employees
- VWAV N/A
- IPHA N/A
- Industry
- VWAV Computer Software: Prepackaged Software
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- VWAV Technology
- IPHA Health Care
- Exchange
- VWAV Nasdaq
- IPHA Nasdaq
- Market Cap
- VWAV 162.2M
- IPHA 160.1M
- IPO Year
- VWAV N/A
- IPHA 2019
- Fundamental
- Price
- VWAV $10.75
- IPHA $1.82
- Analyst Decision
- VWAV
- IPHA Strong Buy
- Analyst Count
- VWAV 0
- IPHA 3
- Target Price
- VWAV N/A
- IPHA $5.00
- AVG Volume (30 Days)
- VWAV 319.8K
- IPHA 572.8K
- Earning Date
- VWAV 11-19-2025
- IPHA 09-17-2025
- Dividend Yield
- VWAV N/A
- IPHA N/A
- EPS Growth
- VWAV N/A
- IPHA N/A
- EPS
- VWAV N/A
- IPHA N/A
- Revenue
- VWAV N/A
- IPHA $14,839,695.00
- Revenue This Year
- VWAV N/A
- IPHA $22.29
- Revenue Next Year
- VWAV N/A
- IPHA $43.84
- P/E Ratio
- VWAV N/A
- IPHA N/A
- Revenue Growth
- VWAV N/A
- IPHA N/A
- 52 Week Low
- VWAV $2.06
- IPHA $1.41
- 52 Week High
- VWAV $18.41
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- VWAV N/A
- IPHA 42.84
- Support Level
- VWAV N/A
- IPHA $1.73
- Resistance Level
- VWAV N/A
- IPHA $1.86
- Average True Range (ATR)
- VWAV 0.00
- IPHA 0.12
- MACD
- VWAV 0.00
- IPHA -0.02
- Stochastic Oscillator
- VWAV 0.00
- IPHA 11.51
About VWAV VisionWave Holdings Inc. Common Stock
VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.